PLEK

Summary

PLEK (pleckstrin, HGNC:9070) is a protein-coding gene on chromosome 2p14, encoding Pleckstrin (P08567). Major protein kinase C substrate of platelets.

Enables phosphatidylinositol-3,4-bisphosphate binding activity; protein homodimerization activity; and protein kinase C binding activity. Involved in several processes, including G protein-coupled receptor signaling pathway; regulation of actin filament organization; and regulation of phosphate metabolic process. Located in cytoplasm and ruffle membrane.

Source: NCBI Gene 5341 — RefSeq curated summary.

At a glance

• Gene–disease (curated): autosomal dominant nonsyndromic hearing loss 58 (Limited, GenCC)
• GWAS associations: 20
• Clinical variants (ClinVar): 50 total
• Druggable target: yes
• MANE Select transcript: NM_002664

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9070
Approved symbol	PLEK
Name	pleckstrin
Location	2p14
Locus type	gene with protein product
Status	Approved
Aliases	P47, PLEK1
Ensembl gene	ENSG00000115956
Ensembl biotype	protein_coding
OMIM	173570
Entrez	5341

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 retained_intron

ENST00000234313, ENST00000474788

RefSeq mRNA: 1 — MANE Select: NM_002664 NM_002664

CCDS: CCDS1887

Canonical transcript exons

ENST00000234313 — 9 exons

Exon	Start	End
ENSE00000758794	68380723	68380904
ENSE00000758796	68382542	68382633
ENSE00000758798	68386502	68386686
ENSE00000758800	68388387	68388491
ENSE00000963053	68380328	68380483
ENSE00001163794	68395680	68397453
ENSE00001911788	68365282	68365393
ENSE00003547803	68394107	68394176
ENSE00003577887	68393162	68393245

Expression profiles

Bgee: expression breadth ubiquitous, 234 present calls, max score 99.08.

FANTOM5 (CAGE): breadth broad, TPM avg 119.7135 / max 9473.8797, expressed in 530 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
20673	114.3031	512
20672	4.3541	335
20686	0.3232	80
20685	0.2758	73
20687	0.1562	58
20689	0.1224	51
20671	0.0997	54
20690	0.0789	38

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	99.08	gold quality
mononuclear cell	CL:0000842	99.01	gold quality
leukocyte	CL:0000738	99.00	gold quality
granulocyte	CL:0000094	98.83	gold quality
blood	UBERON:0000178	98.02	gold quality
bone marrow	UBERON:0002371	97.66	gold quality
bone marrow cell	CL:0002092	97.16	gold quality
lymph node	UBERON:0000029	96.34	gold quality
vermiform appendix	UBERON:0001154	96.19	gold quality
spleen	UBERON:0002106	95.76	gold quality
periodontal ligament	UBERON:0008266	95.43	gold quality
bone element	UBERON:0001474	95.31	gold quality
trabecular bone tissue	UBERON:0002483	94.56	gold quality
caecum	UBERON:0001153	92.44	gold quality
olfactory bulb	UBERON:0002264	91.98	gold quality
type B pancreatic cell	CL:0000169	91.03	gold quality
gall bladder	UBERON:0002110	89.83	gold quality
tongue squamous epithelium	UBERON:0006919	89.48	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.25	gold quality
upper lobe of left lung	UBERON:0008952	88.82	gold quality
upper lobe of lung	UBERON:0008948	87.77	gold quality
rectum	UBERON:0001052	87.75	gold quality
superficial temporal artery	UBERON:0001614	86.95	gold quality
tonsil	UBERON:0002372	85.93	gold quality
right lung	UBERON:0002167	85.66	gold quality
smooth muscle tissue	UBERON:0001135	85.50	gold quality
omental fat pad	UBERON:0010414	85.23	gold quality
peritoneum	UBERON:0002358	85.19	gold quality
right coronary artery	UBERON:0001625	85.09	gold quality
lung	UBERON:0002048	84.68	gold quality

Single-cell (SCXA)

Detected in 31 experiment(s), a significant marker in 29.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	3767.08
E-MTAB-10432	yes	2990.09
E-MTAB-9067	yes	2672.10
E-CURD-98	yes	2281.72
E-MTAB-7407	yes	1880.54
E-GEOD-135922	yes	1745.66
E-CURD-6	yes	1564.42
E-GEOD-130473	yes	1465.43
E-MTAB-8884	yes	1427.00
E-HCAD-6	yes	1327.01
E-GEOD-75688	yes	1021.97
E-ANND-5	yes	619.18
E-HCAD-1	yes	84.78
E-CURD-122	yes	47.35
E-GEOD-84465	yes	39.41

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FLI1, GATA1, LMO2, RUNX1, SPI1

miRNA regulators (miRDB)

54 targeting PLEK, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-1255A	99.74	68.09	744
HSA-MIR-1255B-5P	99.74	68.16	741
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-12122	99.56	69.33	1672
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-12131	99.48	68.72	1673
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-4460	99.37	68.52	615
HSA-MIR-6128	99.33	67.83	1581

Literature-anchored findings (GeneRIF, showing 12)

• Translocation requires its phosphorylation and newly formed ligands (PMID:12054651)
• A pleckstrin homology domain located in G protein-coupled receptor kinase-2 (GRK2) residue 548 to 660 plays a significant role in mediating interaction between protein kinase C beta 1 and GRK2. (PMID:12456365)
• The human pleckstrin-1 solution nuclear magnetic resonance structure of the C-terminal pleckstrin homology domain was reported. (PMID:15698571)
• Proteins beta3 integrin, Vav3, Plekhm1, and Src, implicated in attachment defects, had normal exon sequences in a new type of osteopetrosis. (PMID:19546854)
• Idirect associations between plek and actin through 17 beta-hydroxysteroid dehydrogenase 4, alpha-actinin, moesin, radixin and factor XIIIA, is proposed. (PMID:19722192)
• Here they show that the PH domain from Bcr-Abl binds a number of proteins involved in vital cellular processes in leukemogenesis. (PMID:19944685)
• crystallization and preliminary X-ray diffraction analysis of the first 2 domains of pleckstrin (NPHDEP); work demonstrates that NPHDEP behaves as a monomer in solution and suggests that all 3 pleckstrin domains contribute to the dimerization interface (PMID:21393855)
• These findings reveal a novel role of the PLD1-pleckstrin homology domain as a positive regulator of endocytosis and provide a link between PLD1 and HIF-1alpha in the EGFR endocytosis pathway. (PMID:26680696)
• Only one gene, pleckstrin , was significantly overexpressed in periodontitis,cardiovascular disease, rheumatoid arthritis and ulcerative colitis , implicating this gene as an important networking link between these chronic inflammatory diseases (PMID:26686060)
• A rare genomic duplication in 2p14 underlies autosomal dominant hearing loss DFNA58. (PMID:32337552)
• Pleckstrin Levels Are Increased in Patients with Chronic Periodontitis and Regulated via the MAP Kinase-p38alpha Signaling Pathway in Gingival Fibroblasts. (PMID:35087525)
• Higher expression of PLEK and LY86 as the potential biomarker of carotid atherosclerosis. (PMID:37861500)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	plek	ENSDARG00000104325
mus_musculus	Plek	ENSMUSG00000020120
rattus_norvegicus	Plek	ENSRNOG00000005214

Paralogs (1): PLEK2 (ENSG00000100558)

Protein

Protein identifiers

Pleckstrin — P08567 (reviewed: P08567)

Alternative names: Platelet 47 kDa protein

All UniProt accessions (1): P08567

UniProt curated annotations — full annotation on UniProt →

Function. Major protein kinase C substrate of platelets.

RefSeq proteins (1): NP_002655* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000591	DEP_dom	Domain
IPR001849	PH_domain	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR037370	Pleckstrin	Family
IPR037371	PLEK_DEP	Domain

Pfam: PF00169, PF00610

UniProt features (47 total): strand 24, helix 7, sequence variant 5, domain 3, turn 3, modified residue 3, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

8 structures.

PDB	Method	Resolution (Å)
2I5F	X-RAY DIFFRACTION	1.35
2I5C	X-RAY DIFFRACTION	1.75
1ZM0	X-RAY DIFFRACTION	2.1
1PLS	SOLUTION NMR
1W4M	SOLUTION NMR
1X05	SOLUTION NMR
1XX0	SOLUTION NMR
2CSO	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P08567-F1	82.29	0.39

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 64, 113, 117

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-114608	Platelet degranulation

MSigDB gene sets: 443 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_HEMATOPOIETIC_PROGENITOR_CELL_DIFFERENTIATION, WALLACE_PROSTATE_CANCER_RACE_UP, GOBP_ACTIN_FILAMENT_BUNDLE_ORGANIZATION, GOBP_REGULATION_OF_CALCIUM_MEDIATED_SIGNALING, MCLACHLAN_DENTAL_CARIES_UP, REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION, chr2p14, GOBP_PLATELET_ACTIVATION, MODULE_45, GOBP_INOSITOL_PHOSPHATE_METABOLIC_PROCESS, GOBP_POLYOL_METABOLIC_PROCESS, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_NEGATIVE_REGULATION_OF_ALCOHOL_BIOSYNTHETIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS

GO Biological Process (25): hematopoietic progenitor cell differentiation (GO:0002244), platelet degranulation (GO:0002576), obsolete vesicle docking involved in exocytosis (GO:0006904), phospholipase C-activating G protein-coupled receptor signaling pathway (GO:0007200), integrin-mediated signaling pathway (GO:0007229), positive regulation of platelet activation (GO:0010572), negative regulation of inositol phosphate biosynthetic process (GO:0010920), cell projection organization (GO:0030030), actin cytoskeleton organization (GO:0030036), positive regulation of actin filament depolymerization (GO:0030836), phospholipase C-inhibiting G protein-coupled receptor signaling pathway (GO:0030845), cortical actin cytoskeleton organization (GO:0030866), ruffle organization (GO:0031529), positive regulation of actin filament bundle assembly (GO:0032233), positive regulation of integrin activation (GO:0033625), intracellular signal transduction (GO:0035556), inositol phosphate metabolic process (GO:0043647), negative regulation of G protein-coupled receptor signaling pathway (GO:0045744), negative regulation of calcium-mediated signaling (GO:0050849), regulation of cell diameter (GO:0060305), thrombin-activated receptor signaling pathway (GO:0070493), negative regulation of thrombin-activated receptor signaling pathway (GO:0070495), platelet aggregation (GO:0070527), protein secretion by platelet (GO:0070560), positive regulation of cellular component biogenesis (GO:0044089)

GO Molecular Function (5): protein kinase C binding (GO:0005080), phosphatase activator activity (GO:0019211), protein homodimerization activity (GO:0042803), phosphatidylinositol-3,4-bisphosphate binding (GO:0043325), protein binding (GO:0005515)

GO Cellular Component (6): extracellular region (GO:0005576), cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), membrane (GO:0016020), ruffle membrane (GO:0032587)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Response to elevated platelet cytosolic Ca2+	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
G protein-coupled receptor signaling pathway	3
positive regulation of cytoskeleton organization	2
positive regulation of supramolecular fiber organization	2
intracellular anatomical structure	2
hemopoiesis	1
cell differentiation	1
regulated exocytosis	1
establishment of localization in cell	1
phospholipase C activator activity	1
cell surface receptor signaling pathway	1
regulation of platelet activation	1
platelet activation	1
positive regulation of cell activation	1
negative regulation of phosphorus metabolic process	1
regulation of inositol phosphate biosynthetic process	1
inositol phosphate biosynthetic process	1
negative regulation of carbohydrate metabolic process	1
negative regulation of alcohol biosynthetic process	1
cellular component organization	1
cytoskeleton organization	1
actin filament-based process	1
actin filament depolymerization	1
regulation of actin filament depolymerization	1
positive regulation of protein depolymerization	1
phospholipase C inhibitor activity	1
actin cytoskeleton organization	1
cortical cytoskeleton organization	1
plasma membrane bounded cell projection organization	1
regulation of actin filament bundle assembly	1
positive regulation of cellular component biogenesis	1
actin filament bundle assembly	1
positive regulation of protein-containing complex assembly	1
integrin activation	1
regulation of integrin activation	1
signal transduction	1
organophosphate metabolic process	1
polyol metabolic process	1
regulation of G protein-coupled receptor signaling pathway	1
negative regulation of signal transduction	1

Protein interactions and networks

STRING

4092 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLEK	MCF2	P10911	977
PLEK	OSBP	P22059	908
PLEK	CYTH1	Q15438	905
PLEK	PLCD1	P51178	893
PLEK	SRC	P12931	877
PLEK	AKT1	P31749	867
PLEK	BTK	Q06187	867
PLEK	RABIF	P47224	861
PLEK	CDC42	P21181	844
PLEK	RHOA	P06749	835
PLEK	CYTH3	O43739	814
PLEK	ANK1	P16157	800
PLEK	ANK3	Q12955	799
PLEK	ANK2	Q01484	797
PLEK	RASA1	P20936	791

IntAct

17 interactions, top by confidence:

A	B	Type	Score
PLEK	INPP5A	psi-mi:“MI:0407”(direct interaction)	0.630
PLEK	INPP5A	psi-mi:“MI:0914”(association)	0.630
INPP5A	PLEK	psi-mi:“MI:0914”(association)	0.630
PLEK	WDR75	psi-mi:“MI:0915”(physical association)	0.590
CAVIN2	PLEK	psi-mi:“MI:0915”(physical association)	0.560
PLEK	CAVIN2	psi-mi:“MI:0914”(association)	0.560
PLEK	PF4	psi-mi:“MI:0914”(association)	0.460
	PLEK	psi-mi:“MI:0915”(physical association)	0.400
PLEK	ARHGEF1	psi-mi:“MI:0915”(physical association)	0.400
PLEK	F13A1	psi-mi:“MI:0914”(association)	0.350
	ENO1	psi-mi:“MI:0914”(association)	0.350
SARAF	A2ML1	psi-mi:“MI:0914”(association)	0.350

BioGRID (10): PLEK (Reconstituted Complex), WDR75 (Affinity Capture-MS), PLEK (Affinity Capture-MS), PLEK (Affinity Capture-MS), PLEK (Proximity Label-MS), WDR75 (Affinity Capture-MS), PLEK (Affinity Capture-MS), ARHGEF1 (Affinity Capture-MS), PLEK (Cross-Linking-MS (XL-MS)), PLEK (Proximity Label-MS)

ESM2 similar proteins: O00170, O08915, O75689, O97627, O97628, P08487, P08567, P10686, P16885, P19174, P21146, P24135, P25098, P26817, P26818, P26819, P34512, P35626, P41229, P49619, P49620, P70392, Q09639, Q22070, Q24145, Q38JA7, Q3UYH7, Q4KM33, Q4PMC9, Q5F3R2, Q5FWY5, Q62077, Q64682, Q6IQX0, Q6Q308, Q7YRC1, Q8CIG3, Q8CIH5, Q8NB78, Q8R2V5

Diamond homologs: A0A0G2JUG7, A2A5R2, A5PKW4, A6H7I5, B6RSP1, D3ZL52, D4A631, E1JIT7, F1MUS9, F4IXW2, F4JN05, F4JSZ5, F4K2K3, G3X9K3, G5EET6, G5EGS5, O08967, O13817, O43739, O46382, P08567, P11075, P31749, P31751, P34512, P39052, P39054, P39993, P47102, P47196, P50570, P54644, P60669, P63034, P63035, P97694, P97696, Q00IB7, Q01314, Q10491

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
PRKCA	up-regulates	PLEK	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	0
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1455 predictions. Top by Δscore:

Variant	Effect	Δscore
2:68365390:GAAG:G	donor_gain	1.0000
2:68365394:GTGA:G	donor_loss	1.0000
2:68365395:T:A	donor_loss	1.0000
2:68380322:TTACA:T	acceptor_loss	1.0000
2:68380323:TACA:T	acceptor_loss	1.0000
2:68380326:A:AG	acceptor_gain	1.0000
2:68380326:AG:A	acceptor_gain	1.0000
2:68380326:AGG:A	acceptor_gain	1.0000
2:68380327:G:GG	acceptor_gain	1.0000
2:68380327:G:GT	acceptor_loss	1.0000
2:68380327:GG:G	acceptor_gain	1.0000
2:68380327:GGG:G	acceptor_gain	1.0000
2:68380327:GGGGA:G	acceptor_gain	1.0000
2:68380479:GGATG:G	donor_gain	1.0000
2:68380480:GATG:G	donor_gain	1.0000
2:68380480:GATGG:G	donor_gain	1.0000
2:68380481:ATGG:A	donor_loss	1.0000
2:68380484:G:A	donor_loss	1.0000
2:68380721:A:AG	acceptor_gain	1.0000
2:68380721:AGTTT:A	acceptor_gain	1.0000
2:68380722:G:GC	acceptor_gain	1.0000
2:68380722:GT:G	acceptor_gain	1.0000
2:68380722:GTT:G	acceptor_gain	1.0000
2:68380722:GTTT:G	acceptor_gain	1.0000
2:68380722:GTTTG:G	acceptor_gain	1.0000
2:68380857:G:GT	donor_gain	1.0000
2:68380858:A:T	donor_gain	1.0000
2:68380869:G:GT	donor_gain	1.0000
2:68382531:T:G	acceptor_gain	1.0000
2:68386682:ACTTT:A	donor_gain	1.0000

AlphaMissense

2338 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:68388488:G:C	K253N	1.000
2:68388488:G:T	K253N	1.000
2:68380346:T:A	W21R	0.999
2:68380346:T:C	W21R	0.999
2:68380798:T:A	W92R	0.999
2:68380798:T:C	W92R	0.999
2:68388486:A:G	K253E	0.999
2:68393190:G:C	R264T	0.999
2:68393191:G:C	R264S	0.999
2:68393191:G:T	R264S	0.999
2:68395775:T:A	W338R	0.999
2:68395775:T:C	W338R	0.999
2:68393180:T:A	W261R	0.998
2:68393180:T:C	W261R	0.998
2:68393190:G:T	R264M	0.998
2:68393223:T:C	L275P	0.998
2:68395777:G:C	W338C	0.998
2:68395777:G:T	W338C	0.998
2:68386502:G:A	G158D	0.997
2:68386580:T:C	L184P	0.997
2:68393182:G:C	W261C	0.997
2:68393182:G:T	W261C	0.997
2:68393189:A:G	R264G	0.997
2:68393228:T:G	Y277D	0.997
2:68365383:T:C	L11P	0.996
2:68386523:T:C	L165P	0.996
2:68386678:T:G	Y217D	0.996
2:68388481:T:C	L251S	0.996
2:68388487:A:C	K253T	0.996
2:68393163:G:A	G255E	0.996

dbSNP variants (sampled 300 via entrez): RS1000097883 (2:68393568 G>A), RS1000111924 (2:68373226 A>C,G), RS1000201784 (2:68367252 T>C), RS1000257480 (2:68379034 T>C), RS1000355893 (2:68395213 T>C), RS1000399596 (2:68390874 A>G), RS1000415580 (2:68384491 G>A,T), RS1000527370 (2:68396735 T>C), RS1000533110 (2:68373416 G>A,T), RS1000557788 (2:68373289 G>A), RS1000677038 (2:68378854 G>C,T), RS1000742443 (2:68396719 A>G,T), RS1000846564 (2:68390640 G>A), RS1001089655 (2:68396480 T>A), RS1001130070 (2:68374668 A>G)

Disease associations

OMIM: gene MIM:173570 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
autosomal dominant nonsyndromic hearing loss 58	Limited	Autosomal dominant

Mondo (1): autosomal dominant nonsyndromic hearing loss 58 (MONDO:0014293)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

20 associations (top):

Study	Trait	p-value
GCST000274_1	Metabolite levels	2.000000e-09
GCST000612_20	Celiac disease	8.000000e-09
GCST001198_69	Multiple sclerosis	5.000000e-11
GCST001341_19	Multiple sclerosis	2.000000e-07
GCST002324_1	Anger	4.000000e-06
GCST004607_216	Plateletcrit	2.000000e-14
GCST004627_77	Lymphocyte count	3.000000e-13
GCST005531_106	Multiple sclerosis	1.000000e-13
GCST009030_1	Venous thromboembolism	3.000000e-10
GCST009597_9	Multiple sclerosis	5.000000e-16
GCST90002379_23	Basophil count	4.000000e-09
GCST90002388_72	Lymphocyte count	6.000000e-28
GCST90002392_205	Mean corpuscular volume	2.000000e-12
GCST90002393_191	Monocyte count	1.000000e-14
GCST90002395_327	Mean platelet volume	2.000000e-21
GCST90002397_806	Mean spheric corpuscular volume	8.000000e-13
GCST90002399_145	Neutrophil percentage of white cells	7.000000e-11
GCST90002400_567	Plateletcrit	1.000000e-27
GCST90002401_377	Platelet distribution width	2.000000e-21
GCST90002407_51	White blood cell count	2.000000e-12

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0003015	aggressive behavior
EFO:0007985	platelet crit
EFO:0004587	lymphocyte count
EFO:0005090	basophil count
EFO:0005091	monocyte count
EFO:0007990	neutrophil percentage of leukocytes
EFO:0007984	platelet component distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523171 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tretinoin	increases expression	3
tamibarotene	increases expression	2
Resveratrol	affects cotreatment, increases expression, decreases reaction, increases phosphorylation	2
Benzo(a)pyrene	decreases expression, increases expression	2
Smoke	increases expression, decreases expression, increases abundance	2
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
nickel sulfate	increases expression	1
dioleoylphosphatidic acid	increases phosphorylation, increases reaction	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
phosphatidylethanol	increases phosphorylation, increases reaction	1
CGP 52608	affects binding, increases reaction	1
nutlin 3	affects cotreatment, increases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
licochalcone B	increases expression	1
Pioglitazone	decreases expression	1
Zoledronic Acid	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Cisplatin	increases expression	1
Coal	increases abundance, increases expression	1
Dactinomycin	affects cotreatment, increases expression	1
Diuron	decreases expression	1
Ivermectin	decreases expression	1
Lipopolysaccharides	increases expression, affects response to substance	1
Nickel	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Quercetin	decreases reaction, increases phosphorylation	1
Tetradecanoylphorbol Acetate	decreases reaction, increases phosphorylation	1
Tobacco Smoke Pollution	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4419286	Binding	Binding affinity to PLEK PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	Methods and compositions for inhibiting cnksr1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.